Potassium nitrate powder
Powder
Other
Potassium nitrate is an inorganic salt with a chemical formula of KNO3.
Active ingredients:
Potassium nitrate
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Potassium nitrate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Show details
Therapeutically similar medicines
Show details
Dimethyl sulfoxide 97%-100% solution
Other
97%
Same BNF section
Cholesterol powder
Powder
Same BNF section
Urea powder
Powder
Same BNF section
Magnesium oxide heavy 100mg capsules
Capsule
100mg
Same BNF section
Ammonia solution strong
Other
Same BNF section
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Potassium nitrate
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Chronic heart failure in adults: diagnosis and management (NG106)
NG106
NICE guideline
Updated Sept 2025Chronic heart failure in adults (QS9)
QS9
Quality standard
Updated Sept 2025Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Potassium (K+) is the principal cation modulating the osmotic balance of the body fluids.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
It is established that nitrate is quickly and almost entirely absorbed from the proximal and small intestine subsequent to ingestion in most…
Volume of distribution
Nitrates are absorbed into the general blood circulation and are transported across the body.…
Metabolism
6 months
Nitrates are reduced to nitrites by the bacteria in saliva and the gastrointestinal system .
[L1754]…
[L1754]…
Elimination
Nitrates are excreted in the urine primarily as inorganic nitrates .
[L1754]
[L1754]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Small molecule
About this compound
Potassium nitrate is an inorganic salt with a chemical formula of KNO3. It is a natural source of nitrate and has been used as a constituent for several different purposes, including food preservatives, fertilizers, tree stump removal, rocket propellants, and fireworks. Potassium nitrate is a common active ingredient in toothpaste, exerting an anti-sensitivity action. It provides increasing protection against painful sensitivity of the teeth to cold, heat, acids, sweets or contact [L1754][L1755].
In addition, potassium nitrate is used as a diuretic in pigs, cattle, and horses. It is administered orally doses up to 30 g per animal per day [L1736].
In addition, potassium nitrate is used as a diuretic in pigs, cattle, and horses. It is administered orally doses up to 30 g per animal per day [L1736].
Properties:
solid
Avg. mass: 101.10 Da
DrugBank indication
For the relief of tooth sensitivity, and is also used as a pesticide, insecticide, as a food additive, and a rodenticide .
[L1751][L1754][L1757]
[L1751][L1754][L1757]
Also known as(31)
Potassium nitrate
Eag homolog
Eag-related protein 1
ERG
ERG-1
ERG1
Ether-a-go-go-related gene potassium channel 1
Ether-a-go-go-related protein 1
Dosage forms(33)
Kit; paste (Dental)
Gel, dentifrice (Oral) — 5 g/100g
Suspension (Oral)
Solution (Dental; Oral) — 5 g
Solution (Buccal; Oral)
Gel (Dental; Oral)
Paste, dentifrice (Oral) — 50 mg/1g
Paste (Oral) — 50 mg/1g
Molecular properties(16)
Drug interactions(874)
Known interactions with other medications. Always consult a healthcare professional.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Ramipril.
Fosinopril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Fosinopril.
Trandolapril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Trandolapril.
Benazepril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Benazepril.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Enalapril.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Moexipril.
Lisinopril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Lisinopril.
Perindopril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Perindopril.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Quinapril.
Omapatrilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Omapatrilat.
Rescinnamine
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Rescinnamine.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Captopril.
Cilazapril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Cilazapril.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Spirapril.
Temocapril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Temocapril.
Enalaprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Enalaprilat.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Imidapril.
Zofenopril
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Zofenopril.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Delapril.
Benazeprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Benazeprilat.
Fosinoprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Fosinoprilat.
Ramiprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Ramiprilat.
Trandolaprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Trandolaprilat.
Moexiprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Moexiprilat.
Perindoprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Perindoprilat.
Quinaprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Quinaprilat.
Cilazaprilat
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Cilazaprilat.
Triamterene
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Triamterene.
Spironolactone
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Spironolactone.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Amiloride.
Eplerenone
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Eplerenone.
Canrenoic acid
Unknown severity
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Canrenoic acid.
The risk or severity of hyperkalemia can be increased when Potassium nitrate is combined with Canrenone.
Cefotiam may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cefmenoxime
Moderate
Cefmenoxime may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cefmetazole
Moderate
Cefmetazole may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Pamidronic acid
Moderate
Pamidronic acid may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Tenofovir disoproxil
Moderate
Tenofovir disoproxil may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cidofovir may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cefpiramide
Moderate
Cefpiramide may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Ceftazidime
Moderate
Ceftazidime may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Loracarbef
Moderate
Loracarbef may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cefalotin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cefotaxime
Moderate
Cefotaxime may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Foscarnet may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Methotrexate
Moderate
Methotrexate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Cephalexin
Moderate
Cephalexin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Valaciclovir
Moderate
Valaciclovir may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Bacitracin
Moderate
Bacitracin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Amphotericin B
Moderate
Amphotericin B may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Showing 50 of 874 interactions
Toxicity & overdose
Acute oral toxicity (LD50): 1901 mg/kg in rabbits MSDS and 3750 mg/kg in rats .
[L1736]
The primary acute toxic effect of nitrates is the development of methemoglobinemia, a condition in which greater than 10% of the hemoglobin in the body is transformed into methemoglobin. When this conversion exceeds 70% the condition may result in death .
[L1750]
The potassium ion by itself possesses very little toxicity; the toxicity of the salts is associated with the anion. Potassium nitrate is rapidly absorbed from the upper gastrointestinal tract and is excreted mostly as the unchanged drug .
[L1736]
This excludes a small percentage of the ingested dose that is reduced by the microbial action of the gut to nitrite.
Nitrites convert the hemoglobin in red blood cells into methemoglobin .
[L1736]
In male rats given potassium nitrate, intestinal absorption was affected .
[A32165]
Adverse increased potassium intake included changes in blood lipids, triglyceride, decreased high-density lipoprotein HDL cholesterol), changes in renal function, and increases in catecholamine levels. The decrease in blood volume caused by increased potassium activates the sympathetic nervous system, resulting in the release of adrenaline and noradrenaline. Decreases in blood volume may also contribute to the observed changes in blood lipid concentrations .
[L1755]
Death and severe effects of nitrate ingestion are generally associated with doses of the drugs above 10g NO3-.
Doses ranging from 2-9 g NO3- have been reported to cause methemoglobinemia. These values correspond to 33 - 150 mg NO3-/kg [L1750]
Potassium nitrate was shown to cause low to moderate acute toxicity. Repeated dose toxicity was investigated in rats given oral doses in the range 10-100 mg/kg per day for 4 months; bronchopneumonia, local hemorrhages, and other circulatory disorders were observed in treated animals. Cattle were given oral doses of 345-450 mg/kg daily (expressed as nitrate) for several months; blood phosphate and magnesium were decreased and blood calcium, urinary magnesium, urea and milk urea were increased .
[L1736]
[L1736]
The primary acute toxic effect of nitrates is the development of methemoglobinemia, a condition in which greater than 10% of the hemoglobin in the body is transformed into methemoglobin. When this conversion exceeds 70% the condition may result in death .
[L1750]
The potassium ion by itself possesses very little toxicity; the toxicity of the salts is associated with the anion. Potassium nitrate is rapidly absorbed from the upper gastrointestinal tract and is excreted mostly as the unchanged drug .
[L1736]
This excludes a small percentage of the ingested dose that is reduced by the microbial action of the gut to nitrite.
Nitrites convert the hemoglobin in red blood cells into methemoglobin .
[L1736]
In male rats given potassium nitrate, intestinal absorption was affected .
[A32165]
Adverse increased potassium intake included changes in blood lipids, triglyceride, decreased high-density lipoprotein HDL cholesterol), changes in renal function, and increases in catecholamine levels. The decrease in blood volume caused by increased potassium activates the sympathetic nervous system, resulting in the release of adrenaline and noradrenaline. Decreases in blood volume may also contribute to the observed changes in blood lipid concentrations .
[L1755]
Death and severe effects of nitrate ingestion are generally associated with doses of the drugs above 10g NO3-.
Doses ranging from 2-9 g NO3- have been reported to cause methemoglobinemia. These values correspond to 33 - 150 mg NO3-/kg [L1750]
Potassium nitrate was shown to cause low to moderate acute toxicity. Repeated dose toxicity was investigated in rats given oral doses in the range 10-100 mg/kg per day for 4 months; bronchopneumonia, local hemorrhages, and other circulatory disorders were observed in treated animals. Cattle were given oral doses of 345-450 mg/kg daily (expressed as nitrate) for several months; blood phosphate and magnesium were decreased and blood calcium, urinary magnesium, urea and milk urea were increased .
[L1736]
How it works
Mechanism of action
Potassium (K+) is the principal cation modulating the osmotic balance of the body fluids. In animals, the maintenance of normal cell volume and pressure is dependent on Na+ and K+ pumping [L1759]. Potassium transport through the hydrophobic interior of a cell membrane may be facilitated by several naturally occurring compounds that form lipid-soluble alkali metal cation complexes. Potassium has the critical role of a calcium counter-ion for numerous carboxylates, phosphates, and sulfates, and also acts to stabilize macromolecular structures [L1759].
Potassium is the primary agent for common, over the counter de-sensitizing toothpaste that prevents the transmission of nerve endings to the teeth. Potassium salts, including potassium nitrate, potassium chloride or potassium citrate work by diffusion across the dentinal tubules, causing depolarization of the nerve cells. In turn, these cells become unresponsive to excitatory stimuli. The effect of the potassium nitrate accumulates over time, and it may take several weeks for patients to notice improvement of pain symptoms [L1751].
Potassium nitrates control pests using a unique mechanism of action. Rather than directly poisoning rodents, nitrates support the combustion of charcoal in gas cartridges, promoting the production of toxic gases, which, are lethal to the target pest. The environmental protection agency in the USA (EPA) is only minimally concerned about the risk of direct human exposure to sodium or potassium nitrates, rather than pesticide accidents--typically involving skin burns or inhalation of toxic gases [L1759].
Potassium is the primary agent for common, over the counter de-sensitizing toothpaste that prevents the transmission of nerve endings to the teeth. Potassium salts, including potassium nitrate, potassium chloride or potassium citrate work by diffusion across the dentinal tubules, causing depolarization of the nerve cells. In turn, these cells become unresponsive to excitatory stimuli. The effect of the potassium nitrate accumulates over time, and it may take several weeks for patients to notice improvement of pain symptoms [L1751].
Potassium nitrates control pests using a unique mechanism of action. Rather than directly poisoning rodents, nitrates support the combustion of charcoal in gas cartridges, promoting the production of toxic gases, which, are lethal to the target pest. The environmental protection agency in the USA (EPA) is only minimally concerned about the risk of direct human exposure to sodium or potassium nitrates, rather than pesticide accidents--typically involving skin burns or inhalation of toxic gases [L1759].
Pharmacodynamics
The potassium cation is an essential electrolyte that is important for the maintenance of intracellular osmotic pressure and for the maintenance of cell membrane potential, in particular, the potential of electrically excitable tissues [L1736]. It is a regular component of the diet and is particularly abundant in fruit and vegetables. The recommended daily intake varies from 350-1275 mg in children to 1875 and 5625 mg in adults. In the United Kingdom, the recommended intake is 3.5 g/day for healthy adults [L1736]. Potassium ions are believed to disturb the synapse between nerve cells, thus decreasing nerve excitation and the associated pain [L1751].
Potassium nitrates are ignitable fumigants also utilized as rodenticides and insecticides. They are added to other pesticide active ingredients (sulfur and carbon) and placed into fumigant gas cartridges, designed to be ignited and placed in pest-infested areas. The activated cartridge bombs release toxic gases which are lethal to select rodents, skunks, coyotes, and wasps [L1752].
Potassium ions have demonstrated in animal studies to act directly on the nerves and to reduce sensory activity [L1751]. Tooth hypersensitivity can be relieved by inactivating the intra-dental nerve and inhibiting neural transmission, using suitable medications [L1751].
It has been found that potassium-to-sodium intake ratios are strongly related to cardiovascular disease risk than either nutrient alone. The data describing this relationship warrants further research for various target tissue endpoints [A32167].
Potassium nitrates are ignitable fumigants also utilized as rodenticides and insecticides. They are added to other pesticide active ingredients (sulfur and carbon) and placed into fumigant gas cartridges, designed to be ignited and placed in pest-infested areas. The activated cartridge bombs release toxic gases which are lethal to select rodents, skunks, coyotes, and wasps [L1752].
Potassium ions have demonstrated in animal studies to act directly on the nerves and to reduce sensory activity [L1751]. Tooth hypersensitivity can be relieved by inactivating the intra-dental nerve and inhibiting neural transmission, using suitable medications [L1751].
It has been found that potassium-to-sodium intake ratios are strongly related to cardiovascular disease risk than either nutrient alone. The data describing this relationship warrants further research for various target tissue endpoints [A32167].
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
It is established that nitrate is quickly and almost entirely absorbed from the proximal and small intestine subsequent to ingestion in most animals, with little if any absorption from the stomach and lower intestine .
[L1754]
The vast majority of intestinal K+ absorption occurs in the small intestine; the contribution of the normal colon to net K+ absorption and secretion is trivial .
[A32174]
[L1754]
The vast majority of intestinal K+ absorption occurs in the small intestine; the contribution of the normal colon to net K+ absorption and secretion is trivial .
[A32174]
Volume of distribution
Nitrates are absorbed into the general blood circulation and are transported across the body. Radioactive tracer experiments have demonstrated that nitrates are distributed evenly among body organs, and their rate of distribution depends on blood flow .
[L1754]
[L1754]
Metabolism
Nitrates are reduced to nitrites by the bacteria in saliva and the gastrointestinal system .
[L1754]
The in vivo reduction of nitrates to nitrites depends on conditions that are subject to much variations such the volume and species of microflora present in the saliva/gastrointestinal tract, and stomach pH. Gastric pH is higher in infants younger than 6 months of age and during certain gastrointestinal tract infections, thereby favoring the reduction of nitrates .
[L1754]
Nitrate is metabolized to a small extent. The biotransformation of potassium nitrate consists of nitrate reduction, nitrite formation, nitrite reoxidation to nitrate, and formation of methemoglobin or NO, in a dynamic equilibrium .
[L1752], [L1753], [L1754]
[L1754]
The in vivo reduction of nitrates to nitrites depends on conditions that are subject to much variations such the volume and species of microflora present in the saliva/gastrointestinal tract, and stomach pH. Gastric pH is higher in infants younger than 6 months of age and during certain gastrointestinal tract infections, thereby favoring the reduction of nitrates .
[L1754]
Nitrate is metabolized to a small extent. The biotransformation of potassium nitrate consists of nitrate reduction, nitrite formation, nitrite reoxidation to nitrate, and formation of methemoglobin or NO, in a dynamic equilibrium .
[L1752], [L1753], [L1754]
Route of elimination
Nitrates are excreted in the urine primarily as inorganic nitrates .
[L1754]
[L1754]
Drug targets(1)
Proteins and enzymes this drug interacts with in the body
Voltage-gated inwardly rectifying potassium channel KCNH2
KCNH2
agonist
Specific functiondelayed rectifier potassium channel activity
Cellular location
Cell membrane
General function & pharmacology
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Channel properties are modulated by cAMP and subunit assembly .
PMID:10837251
Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity PMID:10219239 PMID:9230439
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Channel properties are modulated by cAMP and subunit assembly .
PMID:10837251
Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245
Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity PMID:10219239 PMID:9230439
Transporters(1)
Proteins that transport this drug across cell membranes
Mucin-1
MUC1
substrate
Specific functionp53 binding
Cellular location
Apical cell membrane
General function & pharmacology
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack
Scientific references(5)
Grudzinski I., Szymanski A.
The effect of acute poisoning with potassium nitrate and sodium nitrite on the processes of intestinal absorption of D-xylose in rats.
Archives of Environmental Contamination and Toxicology
199121(3):453-461. doi: 10.1007/bf01060370
Weaver C.M.
Potassium and health.
Advanced Nutr
2013 May 14(3):368S-77S. doi: 10.3945/an.112.003533
Schultz D.S., Deen W.M., Karel S.F., Wagner D.A., Tannenbaum S.R.
Pharmacokinetics of nitrate in humans: role of gastrointestinal absorption and metabolism.
Carcinogenesis
19856(6):847-852. doi: 10.1093/carcin/6.6.847
Bychkov R., Gollasch M., Steinke T., Ried C., Luft F.C., Haller H.
Calcium-Activated Potassium Channels and Nitrate-Induced Vasodilation in Human Coronary Arteries.
The Journal of Pharmacology and Experimental Therapeutics
1998285(1):293-298. doi: 10.1016/s0022-3565(24)37378-1
Agarwal R., Afzalpurkar R., Fordtran J.S.
Pathophysiology of potassium absorption and secretion by the human intestine.
Gastroenterology
1994107(2):548-571. doi: 10.1016/0016-5085(94)90184-8
Affected organisms(1)
Humans and other mammals
Experimental properties(3)
Commercial products(291)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Potassium nitrate
Additional database identifiers
Drugs Product Database (DPD)
7157
ChemSpider
22843
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6251
GenAtlas
KCNH2
GeneCards
KCNH2
GenBank Gene Database
U04270
GenBank Protein Database
487738
Guide to Pharmacology
572
UniProt Accession
KCNH2_HUMAN
GenBank Gene Database
U68759
UniProt Accession
P71278_ENTCL
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7508
GenAtlas
MUC1
GeneCards
MUC1
GenBank Gene Database
M21868
UniProt Accession
MUC1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 26 days ago(8 Mar 2026)